Skip to main content
Clinical Trials/NCT04381780
NCT04381780CompletedNot Applicable

Treatment of Fibromyalgia With a Unique Polypeptide Nutritional Support

Practitioners Alliance Network2 sites in 1 country100 target enrollmentStarted: May 6, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
100
Locations
2
Primary Endpoint
Composite VAS

Study Overview

Brief Summary

Treatment of Fibromyalgia and CFS with Recovery Factors

Detailed Description

Use of a unique oral porcine peptide nutritional supplement in those meeting ACR 2010(amended) diagnostic criteria for Fibromyalgia or CDC Criteria for CFS

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Meet the ACR 2010 Amended Fibromyalgia Diagnostic Criteria or CFS CDC criteria; Score 5 or less on Energy VAS

Exclusion Criteria

  • Under 18 Pregnant Other severe complicating conditions

Outcomes

Primary Outcomes

Composite VAS

Time Frame: 6 weeks

Composite of VAS for Fatigue, sleep, cognition, pain and overall well being

Secondary Outcomes

  • FIQ-R(1 month)

Investigators

Sponsor
Practitioners Alliance Network
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials